Prodrugs pp 1023-1039 | Cite as

Miscellaneous Functional Groups

  • Nobuo Shimma
  • Jefferson Tilley
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


This section describes recent examples of prodrugs of functional groups not commonly associated with prodrug strategies, including nitrogen-containing heteroaromatic rings, thiols, nucleic acids, and enediynes. The prodrugs for several addional functional groups that are not covered in this book were reviewed in the book “Design of Prodrugs,” edited by Bundgaard (1985); examples include derivatives of CH acidic compounds, imine bisulphite addition products, and glycosidic products.


Thymidine Phosphorylase Cytidine Deaminase Pyridinium Salt Buthionine Sulfoximine Platelet Activate Factor Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Albert DH, Conway, RG, Magoc TJ, Tapang P, Rhein DA, Luo G, Holms JH, Davidsen SK, Summers J and Carter GW. Properties of ABT-299, a Prodrug of A-85783, a Highly Potent Platelet Activating Factor Receptor Antagonist. J Pharmacol Exp Ther 1996; 277:1595–1606PubMedGoogle Scholar
  2. Arison BH, Braun MP, Cui D, Polsky SL, Rodrigues AD, Vega JM, Vickers S. Preparation of Glucuronide Adducts as GABA Ligand Receptors. 2002; WO 2002090359 A1 20021114 22 ppGoogle Scholar
  3. Bergman R. Reactive 1,4-Dehydroaromatics. Acc Chem Res 1973; 6:25–31CrossRefGoogle Scholar
  4. Bogardus GB, and Higuchi, T. Kinetics and Mechanism of Hydrolysis of Labile Quaternary Ammonium Derivatives of Tertiary Amines. J Pham Sci 1982; 71:729–735CrossRefGoogle Scholar
  5. Borders DB, and Doyle, TW, Eds. Enediyne Antibiotics as Antitumor Agents. Marcel Dekker: New York, 1994Google Scholar
  6. Bradner WT, Rose WC, Schurig JE, and Florczyk AP. Antitumor Activity and Toxicity in Animals of N-7-[2-(4-nitrophenyldithio)ethyl]mitomycin C (BMY-25067). Invest New Drugs 1990; 8(Suppl 1):S1–S7PubMedGoogle Scholar
  7. Bundgaard H, Ed. Design of Prodrugs. New York: Elsevier Science Pub Co; 1985. 360 p.Google Scholar
  8. Dai W-M, Lai KW, Wu A., Hamaguchi W., Lee MYH., Zhou L, Ishii A, and Nishimoto S. DNA Cleavage Potency, Cytotoxicity, and Mechanism of Action of a Novel Class of Enediyne Prodrugs. J Med Chem 2002; 45:758–761PubMedCrossRefGoogle Scholar
  9. Davidsen SK, Summers JB, Albert DH, Holms, JH, Heyman HR, Magoc TJ, Conway RG, Rhein DA, and Carter GW. N-(Acyloxyalkyl)pyridinium Salts as Soluble Prodrugs of a Potent Platelet Activating Fact or Antagonist. J Med Chem 1994; 37:4423–4429.PubMedCrossRefGoogle Scholar
  10. Dirix L, Catimel G, Koier I, Prove A, Schrijvers D, Joossens E, De Bruijin E, Ardiet C, Evene E, Dumortier A, Clavel M, and Van Oosterom A. Phase I and Pharmacokinetic Study of a Novel Mitomycin C Analog KW-2149. Anticancer Drugs 1995, 6, 53–63PubMedCrossRefGoogle Scholar
  11. Doyle TW. and Kadow JF, Eds. Recent Progress in the Chemistry of Enediyne Antibiotics. Tetrahedon Symposia-in print No. 53. Tetrahedron, 1994, 50(5)Google Scholar
  12. Golik J, Matiskella JD, and Ueda Y. Water-soluble Antifungal Prodrugs of Azole Compounds and their Preparation by Quaternization of Azole Ring with Phosphonooxymethyl Group. 2001; US 6235728 B1 20010522 10 ppGoogle Scholar
  13. Grissom JW, Gunawardena GU, Klingberg D, and Huang D. The Chemistry of Enediynes, Enyne Allenes and Related Compounds. Tetrahedron, 1996; 52:6453–6518CrossRefGoogle Scholar
  14. Hattori K, Kohchi Y, Oikawa N, Suda H, Ura M, Ishikawa T, Miwa M, Endoh M, Eda H, Tanimura H, Kawashima A, Horii I, Ishitsuka H, and Shimma N. Design and Synthesis of the Tumor-activated Prodrug of Dihydropyrimidine Dehydrogenase (DPD) Inhibitor, RO0094889 for Combination Therapy with Capecitabine. Bioorg Med Chem Lett 2003; 13:867–872PubMedCrossRefGoogle Scholar
  15. Hay MP., Wilson WR. and Denny WA. A Novel Enediyne Prodrug for Antibody-Directed Enzyme Prodrug Therapy (ADEPT) using E. coli B Nitroreductase. Bioorg Med Chem Lett 1995; 5:2829–2834CrossRefGoogle Scholar
  16. He QY, Maruenda H and Tomaz M. Novel Bioreductive Activation of Mitomycin C Derivatives Bearing a Disulfide Substituent in Their Quinone. J. Am. Chem. Soc. 1994; 116:9349–9350CrossRefGoogle Scholar
  17. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, and Maruyama HB. Role of Uridine Phosphorylase for Antitumor Activity of 5′-Deoxy-5-fluorouridine. Jnp J Cancer Res 1980; 71:112–123.Google Scholar
  18. Ichikawa T, Kitazaki T, Matsushita Y, Yamada M, Hayashi R, Yamaguchi M, Kiyota Y, Okonogi K, and Itoh, K. Optically Active Antifungal Azoles. XII. Synthesis and Antifungal Activity of the Water-Soluble Prodrugs of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H,1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone. Chem Pharm Bull 2001; 49:1102–1109PubMedCrossRefGoogle Scholar
  19. Kohn H, and Wang S. Studies on the Mechanism of Action of C(7) Ethylenediamine Substituted Mytomycins. Relevance to the Proposed Mode of Action of BMY-25067 and KW-2149. Tetrahedron Lett 1996; 37: 2337–2340CrossRefGoogle Scholar
  20. Kono M, Saitoh Y, Kasai M, Saito A, Shirahata K, Morimoto M, and Ashizawa T. Synthesis and Antitumor Activity of a Novel Water-soluble Mitomycin Analog; 7-N-[2-[[2-(?-L-Glutamylamino)ethyl]dithio]ethyl]mitomycin C. Chem Pharm Bull 1989; 37:1128–1130PubMedGoogle Scholar
  21. Koukourakis MI. Amifostine in Clinical Oncology: Current Use and Future Applications. Anticancer Drugs. 2002; 13:181–209PubMedCrossRefGoogle Scholar
  22. Lhermitte H and Grierson DS. The Enediyne and Dienediyne Based Antitumor Antibiotics. Methodology and Strategies for Total Synthesis and Construction of Bioactive Analogs. Part 1. Contemp Org Synth. 1996a; 3:41–63CrossRefGoogle Scholar
  23. Lhermitte H, and Grierson DS. The Enediyne and Dienediyne Based Antitumor Antibiotics. Methodology and Strategies for Total Synthesis and Construction of Bioactive Analogs. Part 2. Contemp Org Synth 1996b; 3: 93–124CrossRefGoogle Scholar
  24. Maier ME. Design of Enediyne Prodrugs. Synlett, 1995; 13–26Google Scholar
  25. Ohwada J, Murasaki C, Yamazaki, T, Ichihara, S, Umeda, I, and Shimma N. Synthesis of Novel Water Soluble Benzylazolium Prodrugs of Lipophilic Azole Antifungals. Bioorg Med Chem Lett 2002; 12:2775–2780PubMedCrossRefGoogle Scholar
  26. Ohwada J, Tsukazaki M, Hayase T, Oikawa N, Isshiki Y, Fukuda H, Mizuguchi E, Sakaitani M, Shiratori Y, Yamazaki T, Ichihara S, Umeda I, and Shimma, N. Design,Synthesis and Antifungal Activity of a Novel Water Soluble Prodrug of Antifungal Triazole. Bioorg Med Chem Lett 2003; 13:191–196PubMedCrossRefGoogle Scholar
  27. Pace GW, and Leaf CD. The Role of Oxidative Stress in HIV Disease. Free Rad Biol Med 1995; 19:523–528PubMedCrossRefGoogle Scholar
  28. Pfister M, Martin, NE, Haskell LP, and Barrett JS. Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240. J Clin Pharmacol 2004: 44:621–631.PubMedCrossRefGoogle Scholar
  29. Robinson CP, Robinson K, and Castaner J. BMS-181174, BMY-25067. Drugs of the Future 1996; 21:999–1002.Google Scholar
  30. Rossi GP. Dual ACE and NEP Inhibitors: A Review of the Pharmacological Properties of MDL 100,240. Cardiovasc Drug Rev 2003; 21:51–66PubMedGoogle Scholar
  31. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Beglinger C, and Weidekamm E. Pharmacokinetics of BAL4815, a New Azole Antifungal, after Administration of Single Ascending Oral Doses of its Pro-Drug BAL8557, 43rd ICAAC 2003. Poster A1-3047 Sep 14–17, 2003, Chicago, IllinoisGoogle Scholar
  32. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Man A, and Roehrle M. Pharmacokinetics of BAL4815, a New Azole Antifungal, after Administration of Single Ascending Intravenous Doses of its Pro-Drug BAL8557. 14th ECCMID 2004. Poster P 1033 May 1–4, 2004, Prague, Czech RepublicGoogle Scholar
  33. Schmitt-Hoffmann A, Roos B, Spickermann J, Weidekamm E, and Roehrle M. Multiple Ascending Dose Pharmacokinetics of the New Antifungal BAL4815 after Intravenous and Oral Administration of its Prodrug BAL8557. 44th ICAAC 2004. Poster A-37, Oct. 30–Nov. 2, 2004, Washington DCGoogle Scholar
  34. Shair MD, Yoon TY, Mosny KK., Chou TC, and Danishefsky SJ. The Total Synthesis of Dynemicin A Leading to Development of a Fully Contained Bioreductively Activated Enediyne Prodrug. J Am Chem Soc 1996; 118:9509–9525CrossRefGoogle Scholar
  35. Shimma N, Umeda, I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y, Miwa M, Ura M, Sawada N, Tahara H, Kuruma I, Horii I, and Ishitsuka H. The Design and Synthesis of a New Tumor-selective Fluoropyrimideine Carbamate, Capecitabine. Bioorg Med Chem 2000; 8:1697–1706PubMedCrossRefGoogle Scholar
  36. Vincentella J, Viré J-C, Paul C, and Looze Y. Vincentella J, Viré J-C, Paul C, and Looze Y. Poly(ethylene glycol) Derivatized Prodrugs through Mixed Disulfide Bond Formation: Preliminary Report on Captopril Int J Pharmaceut 1996; 134:147–155CrossRefGoogle Scholar
  37. Vyas DM, Chiang Y, Benigni D, Rose WC, and Bradner WT. Novel Disulfide Mitosanes as Antitumor Agents. In: Tshigami J Ed Recent Advances in Chemotherapy. Anticancer Section. Tokyo: University of Tokyo Press; 1985:485–486Google Scholar
  38. Wang H, and Kohn K. Studies on the Mode of Action of Mitomycin C(7) Aminoethylene Disulfides (BMS-181174 and KW-2149): Reactivity of 7-N-(mercaptoethyl)mitomycin C. J Med Chem 1999; 42:788–790PubMedCrossRefGoogle Scholar
  39. Xu B, and Singh SV. Effect of Buthionine Sulfoximine and Ethacrynic Acid on Cytotoxic Activity of Mytomycin C Analogues BMY 25282 and BMY 25067. Cancer Res 1992; 52:6666–6670PubMedGoogle Scholar
  40. Yen Y-C, and Au. JL-S. Pharmacodynamic Evaluation of Mytomycin C Analogue BMS-181174 for Potential Use in Intravesical Bladder Cancer Therapy. Pharm Res 1997; 14:241–245PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Nobuo Shimma
    • 1
  • Jefferson Tilley
    • 2
  1. 1.Kamakura Research LaboratoriesChugai Pharmaceutical Co. Ltd.KamakuraJapan
  2. 2.Hoffmann-La Roche Inc.NutleyUSA

Personalised recommendations